The US Food and Drug Administration (FDA) has approved the B-cell depleting agent inebilizumab-cdon (Uplizna, Amgen) for the treatment of immunoglobulin G4-related disease (IgG4-RD). This is the first and only treatment approved for this rare autoimmune disease in the United States. An estimated 200,000 people in the United States are living with IgG4-RD...
TheFeel, námestí Smirických, Kostelec n. C. Lesy 28163, Czechia
+31613054419
info@thefeel.org
Copyright © 2023 news.thefeel.org. All Rights Reserved
